p16^ink4a Gene and Hematological Malignancies

References

• Hartwell L.H., Kastan M.B. Cell cycle control ana cancer. Science 1994; 266: 1821–1828
   PubMed Web of Science ®Google Scholar
• Hunter T., Pines J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573–582
   PubMed Web of Science ®Google Scholar
• Ando K., Griffin J.D. Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells. Oncogene 1995; 10: 751–755
   PubMed Web of Science ®Google Scholar
• Lukas J., Bartkova J., Welcker M., Petersen O.W., Peters G., Strauss M., Bartek J. Cyclin D2 is a moderately oscillating nucleoprotein required for Gl phase progression in specific cell types. Oncogene 1995; 10: 2125–2134
   PubMed Web of Science ®Google Scholar
• Shiekhattar R., Mermelstein F., Fisher R.P., Drapkin R., Dynlacht B., Wessling H.C., Morgan D.O., Reinberg D. Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature 1995; 374: 283–287
   PubMed Web of Science ®Google Scholar
• Murray A. Cyclin ubiquitination: the destructive end of mitosis. Cell 1995; 81: 149–152
   PubMed Web of Science ®Google Scholar
• Peters M., Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1994; 79: 181–184
   PubMed Web of Science ®Google Scholar
• Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cycl in-dependent kinases. Genes dev. 1995; 9: 1149–1163
   PubMed Web of Science ®Google Scholar
• Peters M., Gartner A., Horecka J., Ammerer G., Herskowitz I. FAR1 links the signal transduction pathway to the cell cycle machinery in yeast. Cell 1993; 73: 747–760
   PubMed Web of Science ®Google Scholar
• Schwob E., Bohm T., Mendenhall M.D., Nasmyth K. The B-type cyclin kinase inhibitor p40SIC1 controls the G1 to S tran-sition in S. cerevisiae. Cell 1994; 79: 233–244
   PubMed Web of Science ®Google Scholar
• Moreno S., Nurse P. Regulation of progression through the G 1 phase of the cell cycle by the ruml+ gene. Nature 1994; 367: 236–242
   PubMed Web of Science ®Google Scholar
• Hannon G.J., Casso D., Beach D. KAP: A dual specificity phosphatase that interacts with cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA 1994; 91: 1731–1735
   PubMed Web of Science ®Google Scholar
• Bullrich F., Mac Lachlan T.K., Sang N., Druck T., Veronese M.L., Allen S.L., Chiorazzi N., Koff A., Heubner K., Croce C., Giordano A. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27KiP1 to regions involved in human cancer. Cancer Res. 1995; 55: 1199–1205
   PubMed Web of Science ®Google Scholar
• Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massague J., Roberts J.M., Koff A. p27kiP1 a cyclin-cdk inhibitor links transforming growth factor-b and contact inhibition to cell cycle arrest. Genes Dev. 1994; 8: 9–22
   PubMed Web of Science ®Google Scholar
• Nourse J., Firpo E., Flanagan W.M., Coats S., Polyak K., Lee M-H., Massague J., Crabtree G.R., Roberts J.M. Interleukin-2-mediated elimination of the p27KiP1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372: 570–573
   PubMed Web of Science ®Google Scholar
• Kato J.Y., Matsuoka M., Polyak K., Massague J., Sherr C.J. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27KiP1) of cyclin-dependent kinase 4 activation. Cell 1994; 79: 487–496
   PubMed Web of Science ®Google Scholar
• Ravitz M.J., Yan S., Herr K.D., Wenner C.E. Transforming growth factor beta-induced activation of cylin-E-cdk2 kinase and down regulation of p27KiP1 in C3H 10T1/2 mouse fibroblasts.1,2. Cancer res. 1995; 55: 1413–1416
   PubMed Web of Science ®Google Scholar
• El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825
   PubMed Web of Science ®Google Scholar
• Luo Y., Hurwitz J., Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21cipl. Nature 1995; 375: 159–161
   PubMed Web of Science ®Google Scholar
• Chen J., Jackson P.K., Kirschner M.W., Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 1995; 374: 386–388
   PubMed Web of Science ®Google Scholar
• Fisher D.E., Bodis S., Lowe S., Takemoto C., Housman D., Jacks T. Restoration of apoptosis in p53 deficient tumor cells. Blood 1994; 84, supl, Ab 429
   Web of Science ®Google Scholar
• Skapek S.X., Rhee J., Spicer D.B., Lassar A.B. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin Dl-dependent kinase. Science 1995; 267: 1022–1024
   PubMed Web of Science ®Google Scholar
• Halevy O., Novitch B.G., Spicer D.B., Skapek S.X., Rhee J., Hannon G.J., Beach D., Lassar A.B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267: 1018–1021
   PubMed Web of Science ®Google Scholar
• Steinman R.A., Hoffman B., Iro A., Guillouf C., Liebermann D.A., E1-Houseini M.E. Induction of p21 (WAF-1/C1P1) during differentiation. Oncogene 1994; 9: 3389–3396
   PubMed Web of Science ®Google Scholar
• Parker S.B., Eichele G., Zhang P., Rawls A., Sands A.T., Bradley A., Olson E.N., Harper J.W., Elledge S.J. p53-independent expression of p21ciPl in muscle and other terminally differentiating cells. Science 1995; 267: 1024–1027
   PubMed Web of Science ®Google Scholar
• Matsuoka S., Edwards M.C., Bai C., Parker S., Zhang P., Baldini A., Harper J.W., Elledge S.J. p57KIP2 a structurally distinct member of the p21clpl Cdk inhibitor family, is a condidate tumor suppressor gene. Genes dev. 1995; 9: 650–662
   PubMed Web of Science ®Google Scholar
• Lee M.H., Reynisdottir I., Massague J. Cloning of p57KIP2 a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes dev. 1995; 9: 639–649
   PubMed Web of Science ®Google Scholar
• Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704–707
   PubMed Web of Science ®Google Scholar
• Hannon G.J., Beach D. p15INk48 is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994; 371: 257–261
   PubMed Web of Science ®Google Scholar
• Tarn S.W., Shay J.W., Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res. 1994; 54: 5816–5820
   PubMed Web of Science ®Google Scholar
• Bremmer R., Cohen B.L., Sopta M., Hamel P.A., Ingles C.J., Gallic B.L., Phillips R.A. Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol. Cell. Biol. 1995; 15: 3256–3265
   PubMed Web of Science ®Google Scholar
• Lukas J., Bartkova J., Rohde M., Strauss M., Bartek J. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol. Cell. Biol. 1995; 15: 2600–2611
   PubMed Web of Science ®Google Scholar
• Li Y., Nichols M.A., Shay J.W., Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma suseptibility gene product pRb1. Cancer Res. 1994; 54: 6078–6082
   PubMed Web of Science ®Google Scholar
• Schulze A., Zerfass K., Spitkovsky D., Henglein B., Jansen-Durr P. Activation of the E2F transcriptional factor by cyclin D1 is blocked by p16INK4 the product of the putative tumor suppressor gene MTS1. Oncogene 1994; 9: 3475–3482
   PubMed Web of Science ®Google Scholar
• Lukas J., Parry D., Aagaard L., Mann D.J., Bartkova J., Strauss M., Peters G., Bartek J. Retinoblastoma-protein-de-pendent cell-cycle inhibition by the tumour suppressor p16. Nature 1995; 375: 503–506
   PubMed Web of Science ®Google Scholar
• Parry D., Bates S., Mann D.J., Peters G. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTSI tumour suppressor gene product. EMBO J. 1995; 14: 503–511
   PubMed Web of Science ®Google Scholar
• Yeager T., Stadler W., Belair C., Puthenveettil J., Olopade O., Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res. 1995; 55: 493–497
   PubMed Web of Science ®Google Scholar
• Shapiro G.I., Edwards C.D., Kobzik L., Godleski J., Richards W., Sugarbaker D.J., Rollins B.J. Reciprocal Rb in-activation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 1995; 55: 505–509
   PubMed Web of Science ®Google Scholar
• Otterson G.A., Kratzke R.A., Coxon A., Kim Y.W., Kaye F.J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994; 9: 3375–3378
   PubMed Web of Science ®Google Scholar
• Okamoto A., Hussain S.P., Hagiwara K., Spillare E.A., Rusin M.R., Demetrick D.J., Serrano M., Hannon G.J., Shiseki M., Zariwala M., Xiong Y., Beach D.H., Yokota J., Harris C.C. Mutations in the P16INK4/MTS1/CDKN2, p15ink4b/mtS2, and p 18 genes in primary and metastatic lung cancer. Cancer Res. 1995; 55: 1448–1451
   PubMed Web of Science ®Google Scholar
• Guan K.L., Jenkins C.W., Li Y., Nichols M.A., Wu X., O'Keefe C.L., Matera A.G., Xiong Y. Growth suppression by p19, a p16INK4MTS1. and p14INK4B/MTS2. related CDK6 inhibitor, correlated with wild-type pRb function. Genes & Development 1994; 8: 2939–2952
   PubMed Web of Science ®Google Scholar
• Hirai H., Roussel M.F., Kato J.Y., Ashmun R.A., Sherr C.J. Novel INK4 proteins, p19 and P18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 1995; 15: 2672–2681
   PubMed Web of Science ®Google Scholar
• Ka Ming Chan F., Zhang J., Cheng L., Shapiro D.N., Winoto A. Identification of human and mouse p19, a novel CDK4 andCDK6 inhibitor with homology to p16ink4. Mol. Cell. Biol. 1995; 15: 2682–2688
   PubMed Web of Science ®Google Scholar
• Mao L., Merlo A., Bedi G., Shapiro G.I., Edwards C.D., Rollins B.J., Sidransky D. A novel p16ink4a transcript. Cancer Res. 1995; 55: 2995–2997
   PubMed Web of Science ®Google Scholar
• Stone S., Jiang P., Dayananth P., Tavtigian S.V., Katcher H., Parry D., Peters G., Kamb A. Complex structure and regulation of the p16ink4a locus. Cancer Res. 1995; 55: 2998–2994
   PubMedGoogle Scholar
• Duro D., Bernard O., Delia Valle V., Berger R., Larsen C.J. A new type of p16ink4a/MTSl gene transcript expressed in B-cell malignancies. Oncogene 1995; 11: 21–29
   PubMed Web of Science ®Google Scholar
• Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., Stockert E., Day R.S., Johnson B.E., Skolnick M.H. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436–440
   PubMed Web of Science ®Google Scholar
• Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753–756
   PubMed Web of Science ®Google Scholar
• Knapek D.F., Serrano M., Beach D., Trono D., Walker C.L. Association of rat p 15INK4B/p 16INK4 deletions with mono-somy 5 in kidney epithelial cell lines but not primary renal tumors. Cancer Res. 1995; 55: 1607–1612
   PubMed Web of Science ®Google Scholar
• Ragione F.D., Russo G.L., Oliva A., Mastropietro S., Mancini A., Borrelli A., Casero R.A., Iolascon A., Zappia V. 5′-deoxy-5′-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines. Oncogene 1995; 10: 827–833
   PubMed Web of Science ®Google Scholar
• Liu Q., Neuhausen S., Me Clure M., Frye C., Weaver-Feldhaus J., Gruis N.A., Eddington K., Allalunis-Turner M.J., Skolnick M.H., Fujimura F.K., Kamb A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 1995; 10: 1061–1067
   PubMed Web of Science ®Google Scholar
• Liu Q., Yan Y.-X., Me Clure M., Nakagawa H., Fujimura F., Rustgi A.K. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocaminoma cell lines. Oncogene 1995; 10: 619–622
   PubMed Web of Science ®Google Scholar
• Beltinger C.P., White P.S., Sulman E.P., Maris J.M., Brodeur G.M. No CDKN2 mutations in neuroblastomas. Cancer Res. 1995; 55: 2053–2055
   PubMed Web of Science ®Google Scholar
• He J., Allen J.R., Collins V.P., Allalunis-Turner M.J., Godbout R., Day R.S., James C.D. CDK4 amplification is an alternative mechanism to p 16 gene homozygous deletion in glioma cell lines. Cancer Res. 1994; 54: 5804–5807
   PubMed Web of Science ®Google Scholar
• Quesnel B., Fenaux P., Preudhomme C., Phillipe N., Fournier J., Peyrat J.P. Analysis of p1 6 gene deletion and point mutation in breast carcinoma. British Journal of Cancer
   PubMedGoogle Scholar
• Xu L., Sgroi D., Sterner C.J., Beauchamp R.L., Pinney D.M., Keel S., Ueki K., Rutter J.L., Buckler A.J., Louis D.N., Gusella J.F., Ramesh V. Mutational analysis of CDKN2 (MTSl/p16inkk4) in human breast carcinomas. Cancer Res. 1994; 54: 5262–5264
   PubMedGoogle Scholar
• Washimi O., Nagatake M., Osada H., Ueda R., Koshikawa T., Seki T., Takahashi T., Takahashi T. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res. 1995; 55: 514–517
   PubMed Web of Science ®Google Scholar
• Moulton T., Samara G., Chung W.-Y., Yuan L., Desai R., Sisti M., Bruce J., Tycko B. MTSl/p16/CDKN2 lesions in primary glioblastoma multiforme. Am. J. Pathol. 1995; 146: 613–619
   PubMed Web of Science ®Google Scholar
• Caldas C., Hahn S.A., Da Costa L.T., Redston M.S., Schutte M., Seymour A.B., Weinstein C.L., Hruban R.H., Yeo C.J., Kern S.E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarci-noma. Nature Genetics 1994; 8: 27–32
   PubMed Web of Science ®Google Scholar
• Walker D.G., Duan W., Popovic E.A., Kaye A.H., Tomlinson F.H., Lavin M. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res. 1995; 55: 20–23
   PubMed Web of Science ®Google Scholar
• Jen J., Harper J.W., Bigner S.H., Bigner D.D., Papadopoulos N., Markowitz S., Willson J. K. V., Kinzler K.W., Vogelstein B. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 1994; 54: 6353–6358
   PubMed Web of Science ®Google Scholar
• Giani C., Finocchiaro G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res. 1994; 54: 6338–6339
   PubMed Web of Science ®Google Scholar
• Spruch-C. H., Gonzalez-Zuelta M., Shibata A., Simoneau A.R., Lin M.F., Gonzales F., Tsai Y., Jones P.A. p16 gene in uncultured tumours. Nature 1994; 370: 183–184
   PubMed Web of Science ®Google Scholar
• Cheng J.Q., Jhanwar S.C., Lu Y.Y., Testa J.R. Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res. 1993; 53: 4761–4763
   PubMed Web of Science ®Google Scholar
• Lo K.W., Huang D.P., Lau K.-M. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res. 1995; 55: 2039–2043
   PubMed Web of Science ®Google Scholar
• Zhang S.-Y., Klein-Szanto A. J. P., Sauter E.R., Shafarenko M., Mitsunaga Nobori T., Carson D.A., Ridge J.A., Goodrow T.L. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res. 1995; 54: 5050–5053
   Web of Science ®Google Scholar
• Cairns P., Mao L., Merlo A., Lee D.J., Schwab D., Eby Y., Tokino K., Van der Riet P., Blaugrund J.E., Sidransky D. Rates of p16(MTS1) mutations in primary tumors with 9p loss. Science 1994; 265: 415–416
   PubMed Web of Science ®Google Scholar
• Cheng J.Q., Jhanwar S.C., Klein W.M., Bell D.W., Lee W.C., Altomare D.A., Nobori T., Olopade O.I., Buckler A.J., Testa J.R. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994; 54: 5547–5551
   PubMed Web of Science ®Google Scholar
• Schulz D.C., Vanderveer L., Buetow K.H., Boente K.H., Boente M.P., Ozols R.F., Hamilton T.C., Godwin A.K. Characterization of chromosome 9 in human ovarian neo-plasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN21. Cancer Res. 1995; 55: 2150–2157
   PubMed Web of Science ®Google Scholar
• Reed J.A., Loganzo F., Shea C.R., Walker G.J., Flores J.F., Glendening M., Bogdany J.K., Shiel M.J., Haluska F.G., Fountain J.W., Albino A.P. Loss of expression of the p16/Cyclin-dependent kinase inhibitor 2 tumor Suppressor Gene in Melanocytic lesions correlates with invassive stage of tumor progression. Cancer Res. 1995; 55: 2713–2718
   PubMed Web of Science ®Google Scholar
• Yoshida S., Todori T., Ichikawa Y., Hanai S., Suzuki H., Hori M., Fukao K., Miwa M., Uchida K. Mutations of p16ink4/CDKN2 and p15ink4b genes in biliary tract cancers. Cancer research 1995; 55: 2756–2760
   PubMed Web of Science ®Google Scholar
• Zhou X., Tarmin L., Yin J., Jiang H.Y., Suzuki H., Rhyu M.G., Abraham J.M., Meltzer S.J. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 1994; 9: 3737–3741
   PubMed Web of Science ®Google Scholar
• Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins P. A. T., Ally D.S., Sheahan M.D., Clark W.H., Tucker M.A., Dracopoli N.C. Germline p16 mutations in familial melanoma. Nature Genet. 1994; 8: 15–21
   PubMed Web of Science ®Google Scholar
• Ranade K., Hussussian C.J., Sikorski R.S., Varmus H.E., Goldstein A.M., Tucker M.A., Serrano M., Hannon G.J., Beach D., Dracopoli N.C. Mutations associated with familial melanoma impair p16INK4 function. Nature Genet. 1995; 10: 114–115
   PubMed Web of Science ®Google Scholar
• Gruis N., Van der Velden P.A., Sandkuij L.A., Prins D.E., Feldhaus J.W., Kamb A., Bergman W., Frants R.R. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet. 1995; 10: 351–353
   PubMed Web of Science ®Google Scholar
• Ohta M., Nagai H., Shimizu M., Rasio D., Berd D., Mastrangelo M., Singh A.D., Shields J.A., Shields C.L., Croce C.M., Huebner K. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res. 1994; 54: 5269–5272
   PubMed Web of Science ®Google Scholar
• Mac Geoch C., Bishop J. A. N., Bataille V., Bishop D.T., Frischauf A.M., Meloni R., Cuzick J., Pinney E., Spurr N.K. Genetic heterogeneity in familial malignant melanoma. Hum. Mol. Genet. 1994; 3: 2195–2200
   PubMed Web of Science ®Google Scholar
• Kamb A., Shattuck-Eidens D., Eeles R., Liu Q., Gruis N.A., Hussey D.W., Tran T., Miki Y., Weaver-Feldhaus J., Me Clure M., Aitken J.F., Anderson D.E., Bergman W., Frants R., Goldar D.E., Green A., Me Lennan R., Martin N.G., Meyer L.J., Youl P., Zone J.J., Skolnick M.H. Analysis of the p16INK4a gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 1994; 8: 22–26
   Web of Science ®Google Scholar
• Koh J., Enders G.H., Dynlacht B.D., Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995; 375: 506–510
   PubMed Web of Science ®Google Scholar
• Yang R., Gombart A.F., Serrano M., Koeffler H.P. Mutational effects on the p16INK4a tumor suppressor protein. Cancer Res. 1995; 55: 2503–2506
   PubMed Web of Science ®Google Scholar
• Sun Y., Hildesheim A., Lanier A. E. P., Cao Y., Yao K.T., Raab-Traub N., Yang C.S. No point mutation byt decreased expression of the p 16/MTS1 tumor suppressor gene in na-sopharyngeal carcinomas. Oncogene 1995; 10: 785–788
   PubMed Web of Science ®Google Scholar
• Nishikawa R., Furnari F.B., Lin H., Arap W., Berger M.S., Cavenee W.K., Su Huang H.J. Loos of p16INK4 expression is frequent in high grade gliomas. Cancer Res. 1995; 55: 1941–1945
   PubMed Web of Science ®Google Scholar
• Islam M.Q., Islam K., Levan G., Horvath G. Monochromosome transfers to syrian hamster BHK cells via mi-crocell fusion provide functional evidence for suppressor genes on human chromosome 9 both for anchorage independence and for tumorigenicity. Genes, Chromosomes & Cancer 1995; 12: 115–125
   Web of Science ®Google Scholar
• Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B., Serrano M., Beach D.H., Harris C.C. Mutations and altered expression of p16lNK4 in human cancer. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 11045–11049
   PubMed Web of Science ®Google Scholar
• Serrano M., Gomer-Lahoz E., De Pinho R.A., Beach D., Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995; 267: 249–252
   PubMed Web of Science ®Google Scholar
• Arap W., Nishikawa R., Furnari F.B., Cavenee W.K., Su Huang H.J. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res. 1995; 55: 1351–1354
   PubMed Web of Science ®Google Scholar
• Pollak C., Hagemeijer A. Abnormalities of the short arm of chromosome 9 with partial loss of material in hematologi-cal disorders. Leukemia 1987; 1: 541–548
   PubMed Web of Science ®Google Scholar
• Carroll A.J., Castleberry R.P., Crist W.M. Lack of association between abnormalities of the chromosome 9 short arm and either “lymphomatous” features of T cell phenotype in childhood acute lymphocytic leukemia. Blood 1987; 69: 735–738
   PubMed Web of Science ®Google Scholar
• Offit K., Parsa N.Z., Jhanwar S.C., Filippa D., Wachtel M., Chaganti R. S. K. Clusters of chromosome 9 aberrations are associated with clinico-pathologic subsets of non Hodgkin's Lymphoma. Genes Chromosom. Cancer 1993; 7: 1–7
   PubMed Web of Science ®Google Scholar
• Offit K., Parsa N.Z., Jhanwar S.C., Filippa D., Wachtel M., Chaganti R. S. K. t(9;14) denotes a subset of low grade non-Hodgkin's Lymphoma with plasmacytoid differentiation. Blood 1992; 80: 2594–2599
   PubMed Web of Science ®Google Scholar
• Lillington D.M., Monard S., Johnson P. W. M., Evans M.L., Kearney L.U., Lister T.A., Young B.D., Gibbons B. The t(14;18) in a patient with de novo acute lymphoblastic leukemia is associated with t(8;9). Leukemia 1994; 8: 560–563
   PubMed Web of Science ®Google Scholar
• Levine E.G., Arthur D.C., Machiniicki J., Frizzera G., Hurd D., Peterson B., Gajl-Pelzalska J., Bloomfield C.D. Four new recurring translocations in non Hodgkin's Lymphoma. Blood 1989; 74: 1796
   PubMed Web of Science ®Google Scholar
• Chilcote R.R., Brown E., Rowley J.D. Lymphoblastic leukemia with lymphopatous features associated with abnormalities of the short arm of chromosome 9. New Engl. J. Med. 1985; 286–291
   PubMed Web of Science ®Google Scholar
• Lai J.L., Fenaux P., Pollet J.P., Estienne M.H., Savary J.B., Huart J.J., Deminatti M. Acute lymphocytic leukemia with 9p anomalies. A report of four additional cases and review of the literature. Cancer Genet. Cytogenet. 1988; 33: 99–109
   PubMed Web of Science ®Google Scholar
• Diaz M.O., Rubin C.M., Harden A., Ziemin S., Larson R.A., Le Beau M.M., Rowley J.D. Deletions of interferon genes in acute lymphoblastic leukemia. New Engl. J. Med. 1998; 322: 77–82
   Web of Science ®Google Scholar
• Ogawa S., Hirano N., Sato N., Takahashi T., Hangaishi A., Tanaka K., Kurokawa M., Tanaka T., Mitani K., Yazaki Y., Hirai H. Homozygous loss in the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood 1994; 84: 2431–2435
   PubMed Web of Science ®Google Scholar
• Hebert J., Cayuela M., Berkeley J., Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) dysplay frequent homozygos deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias. Blood 1994; 84: 4038–4044
   PubMed Web of Science ®Google Scholar
• Quesnel B., Preudhomme C., Philippe N., Vanrumbeke M., Dervite I., Lai J.L., Bauters F., Wattel E., Fenaux P. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 1995; 85: 657–663
   PubMed Web of Science ®Google Scholar
• Stranks G., Height S.E., Mitchell P., Jadayel D., Yuille Ma.R., De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L., Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D., Millar J.L., Catovsky D., Dyer M. J. S. Deletions and rearrangement of CDKN 2 in lymphoid malignancy. Blood 1995; 85: 893–901
   PubMed Web of Science ®Google Scholar
• Otsuki T., Lark H.M., Wellmann A., Jaffe E.S., Raffeld M. Involvement of CDKN2 (p16INK4a/MTS1) and p15INK4B/mts2 in human leukemias and lymphomas. Cancer Res. 1995; 55: 1436–1440
   PubMed Web of Science ®Google Scholar
• Still H., Goldman J.M., Cross N. C. P. Homozygous deletions in the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995; 85: 2013–2016
   PubMed Web of Science ®Google Scholar
• Okuda T., Shurtleff S.A., Valentine M.B., Raimondi S.C., Head D.R., Behm F., Curcio-Brint A.M., Liu Q., Pui C.H., Sherr C.J., Beach D., Look A.T., Downing J.R. Frequent deletion of p 16INDK4a/MTS1 and p 15INK4b/MTS2 in pedi-atric acute lymphoblastic leukemia. Blood 1995; 85: 2321–2330
   PubMed Web of Science ®Google Scholar
• Fizzotti M., Cimino G., Pisegna S., Alimena G., Quartarone C., Mandelli F., Pelicci P.G., Lo Coco F. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 1995; 85: 2685–2690
   PubMed Web of Science ®Google Scholar
• Rasool O., Heyman M., Brandter L.B., Liu Y., Grander D., Soderhall S., Einhorn S. p 15ink4B and p16ink4 gene in-activation in acute lymphocytic leukemia. Blood 1995; 85: 3431–3436
   PubMed Web of Science ®Google Scholar
• Haidar M.A., Cao X.B., Manshouri T., Chan L.L., Glassman A., Kantarjian H.M., Keating M.J., Beran M., Albitar M. p16Ink4a or p15ink4b gene deletions in primary leukemias. Blood 1995; 86: 311–315
   PubMed Web of Science ®Google Scholar
• Takeuchi S., Bartram C.R., Seriu T., Miller C.W., Tobler A., Janssen J. W. G., Reiter A., Ludwig W.D., Zimmermann M., Schwaller J., Lee E., Miyoshi I., Koeffler P. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995; 86: 755–760
   PubMed Web of Science ®Google Scholar
• Delmer A., Tang A., Beaufort C.S., Paterlini P., Brechot C., Zittoun R. Alterations of cyclin dependent kinase 4 inhibitor (p 16Ink4a/MTS1) gene structure and expression in acute lymphoblastic leukemias. Leukemia 1995; 9: 1240–1245
   PubMed Web of Science ®Google Scholar
• Diaz M.O., Pomykala H.M., Bohlander S.K., Maltepe E., Malik K., Brownstein B., Olopade O.I. Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics 1994; 22: 540–552
   PubMed Web of Science ®Google Scholar
• Hsiao M.H., Yu A.L., Yeargin J., Ku D., Haas M. Non hereditary p53 mutations in T-cell Acute Lymphoblastic Leukemia are associated with the relapse phase. Blood 1994; 83: 2922–2930
   PubMed Web of Science ®Google Scholar
• Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematological malignancies. Blood 1994; 84: 3148–3157
   PubMed Web of Science ®Google Scholar
• Döhner H., Fisher K., Bentz M., Hansen K., Benner A., Cabot G., Diehl D., Schlenk R., Coy J., Stilgenbauer S., Volkman M., Galle P.R., Poutska A., Hunstein W., Lichter P. p53 gene deletion predicts for poor survival and non response to therapy with purine analogs in Chronic B-C11 leukemia. Blood 1995; 85: 1580–1589
   PubMed Web of Science ®Google Scholar
• Hata Y., Hirama T., Miller C.W., Yamada Y., Tomonaga M., Koeffler P. Homozygous deletions in the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 1995; 85: 2699–2704
   PubMed Web of Science ®Google Scholar
• Nakai H., Misawa S., Toguchida J., Yandel D.W., Ishizaki K. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of chromosome 17p. Cancer Res. 1992; 52: 6588
   PubMed Web of Science ®Google Scholar
• Fenaux P., Jonveaux P., Quiquandon I., Laï J.L., Pignon J.M., Loucheux Lefebvre M.H., Bauters F., Kerckaert J.P. p53 gene mutations in myeloid leukemia with 17p monosomy. Blood 1991; 80: 1652–1657
   Google Scholar
• Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R. p53 mutations in human lymhoid malignancies associated with Burkitt's lymphoma and chronic lymphocytic leukemia. Proc. Nat. Acad. Sci. USA 1991; 88: 5413–5417
   PubMed Web of Science ®Google Scholar
• Sander C.A., Yano T., Clark H.M., Harris C., Longo D.L., Jaffe E.S., Raffeld M. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 1994–2004
   PubMed Web of Science ®Google Scholar
• Golub T.R., Barker G.F., Lovett M., Gilliland G. Fusion of PDGF receptor B to a novel ets-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal transloca-tion. Cell 1994; 77: 307–316
   PubMed Web of Science ®Google Scholar
• Wlodarska C., Meccucci C., Marynen P., Guo C., Franckx D., La Starza R., Aventin A., Bosly A., Martelli M.F., Cassiman J.J., Van Den Berghe H. TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33:p13) translocation or its variants t(10;12)(q24;p13). Blood 1995; 85: 2848–2852
   PubMed Web of Science ®Google Scholar
• Pietenpol J.A., Bohlander S.K., Sato Y., Papadopoulos N., Liu B., Friedman C., Trask B.J., Roberts J.M., Kinzler K.W., Rowley J.D., Vogelstein B. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 1995; 55: 1206–1210
   PubMed Web of Science ®Google Scholar
• Ponce Castaneda M.V., Lee M.H., Lares E., Polyak K., Lacombe L., Montgomery K., Mathew S., Krauter K., Sheinfeld J., Massegue J., Cordon-Cardo C. p27KiP1: chromosomal mapping to 12pl2–12pl3.1 and absence of mutations in human tumors. Cancer Res. 1995; 55: 1211–1214
   PubMed Web of Science ®Google Scholar
• Delmer A., Ajchenbaum-Cymbalista F., Tang R., Ramond S., Faussat A.M., Marie J.P., Zittoun R. Overexpression of cyclin D2 in Chronic B-Cell malignancies. Blood 1995; 85: 2870–2876
   PubMed Web of Science ®Google Scholar
• De Boer C.J., Loyson S., Kluin P.M., Kluin-Nelemans H.C., Schuuring E., Van Krieken J. H. J. M. Multiple breakpoints within the BCL1 locus in B-Cell Lymphoma: Rearrangements of the cyclin D1 gene. Cancer Res. 1993; 53: 4148–4152
   PubMed Web of Science ®Google Scholar
• Jadayel D., Matutes E., Dyer M. J. S., Brito-Babapulle V., Khohkar M.T., Oscier D., Catowski D. Splenic lymphoma with villous lymphocytes: analysis of BCL1 rearrangements and expression of the cyclin D1 gene. Blood 1994; 83: 3664
   PubMed Web of Science ®Google Scholar
• Furukawa Y., Terui Y., Sakoe K., Ohta M., Kitagawa S., Miura Y., Saito M. Over-expression and amplification of the CDC2 gene in leukaemia cells. Br. J. Haematol. 1995; 90: 94–99
   PubMed Web of Science ®Google Scholar
• Apian P.D., Lombardi D.P., Ginsberg A.M., Cossman J., Bertness V.L., Kirsh I.R. Disruption of the human SCL locus by illegitimate VDJ recombinase activity. Science 1990; 250: 1426
   PubMed Web of Science ®Google Scholar
• Brown L., Cheng J.T., Chen Q., Siliciano M.J., Crist W., Buchanan G., Baser R. Site specific recombination of the tal 1 gene is a common occurence in human T cell leukemia. EMBO J. 1990; 9: 3343
   PubMed Web of Science ®Google Scholar